A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

This study is testing a new CAR T-cell therapy called OriCAR-017 for people with relapsed or refractory multiple myeloma — a blood cancer that has come back or stopped responding to treatment. CAR T-cell therapy engineers your own immune cells to attack cancer cells. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple myeloma that has relapsed or not responded to at least 3 prior treatments - You have received prior BCMA-targeted therapy - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - You have active infections or severe organ problems - You have had recent major surgery - You cannot tolerate the required procedures Talk to your doctor to see if this trial is right for you.